Literature DB >> 9060042

Ibuprofen inhibits the metabolism of the endogenous cannabimimetic agent anandamide.

C J Fowler1, A Stenström, G Tiger.   

Abstract

A measure of the metabolism of anandamide, an endogenous cannabimimetic agent, by rat cerebellar membrane preparations was obtained by following the time-dependent reduction in potency of this compound towards inhibition of binding of the high-affinity cannabinoid agonist ligand [3H]WIN 55212-2 to cannabinoid receptors. Thus for example, incubation of the membranes with 100 nM anandamide for 0, 10 and 30 min. prior to addition of [3H]WIN 55212-2 and phenylmethylsulphonyl fluoride (to inhibit the activity of anandamide amidase, thereby blocking further anandamide metabolism during the binding assay) produced 57 +/- 3, 38 +/- 5 and 19 +/- 7% inhibition, respectively, of [3H]WIN 55212-2 binding. This time-dependent effect was blocked by ibuprofen but not by acetyl salicylic acid, sulindac, acetaminophen or to any significant extent by ketoprofen and naproxen. Preliminary experiments using a direct assay of anandamide amidase with [14C]anandamide as ligand gave an IC50 value for ibuprofen of approximately 400 microM. The potency of ibuprofen as an inhibitor of anandamide metabolism was of the same order of magnitude as required for inhibition of cyclooxygenase-2 in cell-free systems and of the peak plasma concentrations of this drug following a 2 x 200 mg dose regimen. It is concluded that following therapeutic doses of ibuprofen, the metabolism of anandamide may be affected.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9060042     DOI: 10.1111/j.1600-0773.1997.tb00291.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  15 in total

1.  Pain management for dentists: the role of ibuprofen.

Authors:  Alessandro Pozzi; Luca Gallelli
Journal:  Ann Stomatol (Roma)       Date:  2012-04-15

Review 2.  A Double Whammy: Targeting Both Fatty Acid Amide Hydrolase (FAAH) and Cyclooxygenase (COX) To Treat Pain and Inflammation.

Authors:  Rita Scarpelli; Oscar Sasso; Daniele Piomelli
Journal:  ChemMedChem       Date:  2015-10-21       Impact factor: 3.466

Review 3.  Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation.

Authors:  Daniel J Hermanson; Joyonna C Gamble-George; Lawrence J Marnett; Sachin Patel
Journal:  Trends Pharmacol Sci       Date:  2014-05-18       Impact factor: 14.819

4.  Effects of COX-2 inhibition on spinal nociception: the role of endocannabinoids.

Authors:  L E Staniaszek; L M Norris; D A Kendall; D A Barrett; V Chapman
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

5.  Differences in the pharmacological properties of rat and chicken brain fatty acid amidohydrolase.

Authors:  C J Fowler; M Börjesson; G Tiger
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

6.  Inhibition of FAAH, TRPV1, and COX2 by NSAID-serotonin conjugates.

Authors:  Tyler M Rose; Christopher A Reilly; Cassandra E Deering-Rice; Clinton Brewster; Chelsea Brewster
Journal:  Bioorg Med Chem Lett       Date:  2014-10-28       Impact factor: 2.823

7.  TRPV1 in brain is involved in acetaminophen-induced antinociception.

Authors:  Christophe Mallet; David A Barrière; Anna Ermund; Bo A G Jönsson; Alain Eschalier; Peter M Zygmunt; Edward D Högestätt
Journal:  PLoS One       Date:  2010-09-17       Impact factor: 3.240

Review 8.  Cannabinoid system and cyclooxygenases inhibitors.

Authors:  H Păunescu; O A Coman; L Coman; I Ghiţă; S R Georgescu; F Drăghia; I Fulga
Journal:  J Med Life       Date:  2011-02-25

9.  Oral ibuprofen differentially affects plasma and sweat lipid mediator profiles in healthy adult males.

Authors:  Karan Agrawal; Rémy Bosviel; Brian D Piccolo; John W Newman
Journal:  Prostaglandins Other Lipid Mediat       Date:  2018-05-17       Impact factor: 3.072

10.  Evidence against the presence of an anandamide transporter.

Authors:  Sherrye T Glaser; Nada A Abumrad; Folayan Fatade; Martin Kaczocha; Keith M Studholme; Dale G Deutsch
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.